Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

Similar Items

• Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
  od: Xiaoying Sun, i dr.
  Izdano: (2019-06-01)
• Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis
  od: Sun, Xiaoying, i dr.
  Izdano: (2017)
• Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
  od: Zhao, Bin, i dr.
  Izdano: (2020)
• Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
  od: Zhang, Yan, i dr.
  Izdano: (2011)
• The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
  od: Guan, Xiuwen, i dr.
  Izdano: (2016)